XOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital Hyperinsulinism
19 oct. 2016 09h00 HE
|
XOMA Ltd.
BERKELEY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today the United Kingdom’s...
XOMA Provides Update from Ongoing Phase 2 XOMA 358 Clinical Studies
15 sept. 2016 19h26 HE
|
XOMA Ltd.
Results Demonstrate XOMA 358 Mechanism-of-Action in Rare Endocrine ConditionsCompany Plans to Advance XOMA 358 to Multi-dose Phase 2b Studies BERKELEY, Calif., Sept. 15, 2016 (GLOBE...
XOMA to Present at the 2016 Wedbush PacGrow Healthcare Conference
11 août 2016 14h32 HE
|
XOMA Corporation
BERKELEY, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the...
XOMA Reports Second Quarter 2016 Achievements and Financial Results
03 août 2016 16h01 HE
|
XOMA Corporation
BERKELEY, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent achievements and...
XOMA Receives Orphan Drug Designation in the European Union for XOMA 358 for Treatment of Congenital Hyperinsulinism
20 juil. 2016 09h00 HE
|
XOMA Corporation
XOMA 358 previously secured Orphan Drug Designation from the FDA for the treatment of Congenital Hyperinsulinism (CHI)Phase 2 clinical studies currently enrolling patients with CHI in the United...
XOMA to Present at the Cantor Fitzgerald Healthcare Conference
05 juil. 2016 14h05 HE
|
XOMA Corporation
BERKELEY, Calif., July 05, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that Dr. Paul Rubin, the...
InSpark Technologies Announces the Results of the Home Use and Human Factors Study of Vigilant(TM) in People with Diabetes
11 juin 2016 11h00 HE
|
InSpark Technologies
Vigilant met or exceeded all human factors criteria for safety, comprehension and ease of useEarly evidence of clinical benefit was demonstrated by a 51 percent reduction in the proportion of blood...
XOMA to Present at the Jefferies Global Healthcare Conference
02 juin 2016 13h48 HE
|
XOMA Corporation
BERKELEY, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the...
InSpark Technologies Enters into Clinical Trial Collaborations to Study the Effectiveness of Mobile Health Technology in Preventing Low Blood Sugars in People With Diabetes
05 mai 2016 08h00 HE
|
InSpark Technologies
CHARLOTTESVILLE, Va., May 05, 2016 (GLOBE NEWSWIRE) -- InSpark Technologies, Inc. announced today that it has entered into clinical study collaborations with Atlanta Diabetes Associates, a large...
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
04 mai 2016 16h01 HE
|
XOMA Corporation
BERKELEY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational...